{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:48:46Z","timestamp":1790952526089,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"am","delay-in-days":356,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013342","name":"NIHR Imperial Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013342","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1 TR002319"],"award-info":[{"award-number":["UL1 TR002319"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023178","name":"Cancer Treatment and Research Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023178","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["T32CA009515"],"award-info":[{"award-number":["T32CA009515"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016338","name":"Imperial Experimental Cancer Medicine Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016338","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["PS3416"],"award-info":[{"award-number":["PS3416"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.clgc.2022.06.001","type":"journal-article","created":{"date-parts":[[2022,6,5]],"date-time":"2022-06-05T01:15:47Z","timestamp":1654391747000},"page":"e440-e452","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3258-2984","authenticated-orcid":false,"given":"Dimitrios","family":"Makrakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafee","family":"Talukder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevieve Ihsiu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonidas N.","family":"Diamantopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Dawsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Carril-Ajuria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"de Kouchkovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadim S.","family":"Koshkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajjai","family":"Alva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet A.","family":"Bilen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler F.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana R.","family":"McKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishita","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Vather-Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousef","family":"Zakharia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Morales-Barrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Devitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Cortellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia Angela Maria","family":"Fulgenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Pinato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Hoimes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin A.","family":"Gartrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Sankin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roubini","family":"Zakopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aristotelis","family":"Bamias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jure","family":"Murgic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Fr\u00f6be","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejo","family":"Rodriguez-Vida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Drakaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Di","family":"Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Isaacsson-Velho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia Alonso","family":"Buznego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Duran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Moses","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Barata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guru","family":"Sonpavde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan Y.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Bruce","family":"Montgomery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Grivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Raza","family":"Khaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2022.06.001_bib0001","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.2147\/TCRM.S158753","article-title":"Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook","volume":"14","author":"Gopalakrishnan","year":"2018","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.clgc.2022.06.001_bib0002","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2022.06.001_bib0003","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2022.06.001_bib0004","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2022.06.001_bib0005","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: A phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2022.06.001_bib0006","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/jnci\/djt015","article-title":"Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy","volume":"105","author":"Apolo","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clgc.2022.06.001_bib0007","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1200\/JCO.2009.25.4599","article-title":"Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens","volume":"28","author":"Bellmunt","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2022.06.001_bib0008","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1200\/JCO.1999.17.10.3173","article-title":"Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy","volume":"17","author":"Bajorin","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2022.06.001_bib0009","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1097\/JU.0000000000001199","article-title":"Five-factor prognostic model for survival of post-platinum patients with metastatic urothelial carcinoma receiving PD-L1 inhibitors [published correction appears in J Urol. 2021 Mar;205(3):942]","volume":"204","author":"Sonpavde","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2022.06.001_bib0010","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.euo.2020.12.006","article-title":"A new prognostic model in patients with advanced urothelial carcinoma treated with first-line immune checkpoint inhibitors","volume":"4","author":"Khaki","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.clgc.2022.06.001_bib0011","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41416-019-0686-0","article-title":"A model combining clinical and genomic factors to predict response to PD-1\/PD-L1 blockade in advanced urothelial carcinoma","volume":"122","author":"Nassar","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2022.06.001_bib0012","doi-asserted-by":"crossref","unstructured":"Balar AV, Galsky MD, Rosenberg JE, et\u00a0al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. The Lancet. 2017;389:67-76. doi:10.1016\/S0140-6736(16)32455-2.","DOI":"10.1016\/S0140-6736(16)32455-2"},{"key":"10.1016\/j.clgc.2022.06.001_bib0013","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2022.06.001_bib0014","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/annonc\/mdz127","article-title":"Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up","volume":"30","author":"Fradet","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2022.06.001_bib0015","doi-asserted-by":"crossref","unstructured":"Nelson AA, Cronk RJ, Lemke EA, et\u00a0al. Early bone metastases are associated with worse outcomes in metastatic urothelial carcinoma. Bladder Cancer. 2021;7:33-42. doi:10.3233\/BLC-200377.","DOI":"10.3233\/BLC-200377"},{"key":"10.1016\/j.clgc.2022.06.001_bib0016","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/cncr.32645","article-title":"Impact of performance status on treatment outcomes: a real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors","volume":"126","author":"Khaki","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2022.06.001_bib0017","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/JU.0000000000000761","article-title":"Histological subtypes and response to PD-1\/PD-L1 blockade in advanced urothelial cancer: a retrospective study","volume":"204","author":"Miller","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2022.06.001_bib0018","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/bju.15324","article-title":"Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes","volume":"128","author":"Esagian","year":"2021","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2022.06.001_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.clgc.2022.06.001_bib0020","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.clgc.2022.06.001_bib0021","article-title":"Efficacy of enfortumab vedotin in advanced urothelial cancer: analysis from the urothelial cancer network to investigate therapeutic experiences (UNITE) study [published online ahead of print, 2021 Dec 9]","author":"Koshkin","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2022.06.001_bib0022","first-page":"S1558","article-title":"Role of bone metastases in patients receiving immunotherapy for pre-treated urothelial carcinoma: the multicentre, retrospective meet-URO-1 bone study [published online ahead of print, 2021 Dec 16]","author":"Raggi","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2022.06.001_bib0023","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.eururo.2019.10.004","article-title":"Clinical outcome after progressing to frontline and second-line Anti\u2013PD-1\/PD-L1 in advanced urothelial cancer","volume":"77","author":"G\u00f3mez de Lia\u00f1o Lista","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2022.06.001_bib0024","first-page":"437","article-title":"Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors","volume":"39","author":"Ma","year":"2021","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"10.1016\/j.clgc.2022.06.001_bib0025","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.eururo.2018.09.022","article-title":"The cancer immunogram as a framework for personalized immunotherapy in urothelial cancer","volume":"75","author":"van Dijk","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2022.06.001_bib0026","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.eururo.2018.12.005","article-title":"The cancer immunogram: a pledge for a comprehensive biomarker approach for personalized immunotherapy in urothelial cancer","volume":"75","author":"Zahoor","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2022.06.001_bib0027","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.eururo.2018.06.028","article-title":"Evolution of PD-1 and PD-L1 gene and protein expression in primary tumors and corresponding liver metastases of metastatic bladder cancer","volume":"74","author":"Eckstein","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2022.06.001_bib0028","article-title":"Integrative clinical and genomic characterization of mtap-deficient metastatic urothelial cancer","volume":"14","author":"Alhalabi","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.clgc.2022.06.001_bib0029","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1038\/ng.3692","article-title":"Clonal evolution of chemotherapy-resistant urothelial carcinoma","volume":"48","author":"Faltas","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.clgc.2022.06.001_bib0030","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(21)00094-2","article-title":"Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV201): a multicentre, single-arm, phase 2 trial [published correction appears in Lancet Oncol. 2021 Jun;22(6):e239]","volume":"22","author":"Yu","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2022.06.001_bib0031","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13112741","article-title":"Making patient-specific treatment decisions using prognostic variables and utilities of clinical outcomes","volume":"13","author":"Msaouel","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.clgc.2022.06.001_bib0032","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41568-021-00347-z","article-title":"Systemic immunity in cancer","volume":"21","author":"Hiam-Galvez","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clgc.2022.06.001_bib0033","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.568279","article-title":"Current perspectives on immunotherapy in the perioperative setting of muscle-infiltrating bladder cancer","volume":"10","author":"Zucali","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.clgc.2022.06.001_bib0034","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2022.06.001_bib0035","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"issue":"15_suppl","key":"10.1016\/j.clgc.2022.06.001_bib0036","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1200\/JCO.2021.39.15_suppl.4504","article-title":"Pembrolizumab (pembro) in combination with gemcitabine (Gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIBC): a multicenter phase 2 trial","volume":"39","author":"Balar","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.clgc.2022.06.001_bib0037","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1200\/JCO.2020.38.6_suppl.542","article-title":"Impact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cancer: NEODURVARIB trial","volume":"38","author":"Rodriguez-Moreno","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2022.06.001_bib0038","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1038\/s41591-020-1085-z","article-title":"Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial","volume":"26","author":"van Dijk","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.clgc.2022.06.001_bib0039","doi-asserted-by":"crossref","first-page":"viii726","DOI":"10.1093\/annonc\/mdy424.039","article-title":"A phase Ib\/II study of neoadjuvant pembrolizumab (pembro) and chemotherapy for locally advanced urothelial cancer (UC)","volume":"29","author":"Hoimes","year":"2018","journal-title":"Ann Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767322001252?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767322001252?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:35:49Z","timestamp":1761564949000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767322001252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S1558767322001252"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2022.06.001","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2022.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}